RNA polymerase II pausing is the major regulatory point in transcription in higher eukaryotes.
Introduction
Our understanding of transcriptional regulation by RNA polymerase II has undergone major revisions over the past several years. Next generation sequencing experiments have shed light on the behavior of RNA pol II in vivo and transformed the problem of understanding the regulation of pol II. The initial view of pol II transcriptional regulation assigned the primary regulatory point to the proximal promoter region (consisting of various core promoter elements and thereby permits pol II release and elongation. The addition of Sarkosyl to the CFS after a 5' chase (and then extending the chase an additional 5') releases a fraction of +20/+75 RNAs into longer species, in contrast to a 10' chase without Sarkosyl (compare lanes 1 and 2, Fig. 2A ). The second important point here is that the +20/+75 RNAs are remarkably stable, with very little chase into longer products even after allowing the chase to occur for 10'. This experiment shows that the +20/+75 RNAs consist of functional, engaged paused polymerases that can elongate after Sarkosyl addition but otherwise do not chase. This is in contrast to other published elongation systems where the entire pol II population will chase and thus do not represent paused pol II populations 11 . We note that, as with the THZ-induced release, the Sarkosyl-induced release pol II does not efficiently elongate as no increase in full-length products was seen. This suggests that this release is an aberrant release and that other steps have been bypassed that would otherwise permit efficient elongation into the 548 nt product.
GST-SPT5 Stimulates Elongation in the CFS
The DSIF complex is one of two known pausing factors 8 . As such, one might expect that the addition of rSPT5 would stimulate elongation, either by a squelching mechanism where it titrated out other pausing factors, or through its positive elongation activity. To that end, equivalent amounts of either rGST or rGST-SPT5 were titrated into the CFS after PIC formation.
After a 10' incubation, the standard pulse-chase assay was done (Fig. 2B ). As can be seen, the addition of GST-SPT5 stimulated release of the +20/+75 RNA/paused pol II population, as there is a diminution of RNA around +20 and a concomitant increase of RNA longer than +75 (lanes 6-8), while GST protein alone had little effect (lanes 2-5). This experiment indicates that the CFS contains a pol II population that is responsive to SPT5 and that these pol IIs represent a paused population. Lastly, elongation again was not efficient as no increase in full-length products was seen, indicating that the aberrant release skips steps required for efficient elongation.
Lastly, the strong viral SV40 promoter was used to ask if another promoter could establish a paused pol II population in the CFS. The SV40 promoter was one of the first promoters suggested to have a paused pol II 26 . Titration of the SV40 promoter DNA into the CFS clearly showed the establishment of a paused pol II population between +20 and +75 (lanes 1-5, Figure   2C ). This shows that pausing occurs as a default event on two different promoters, but nevertheless, ones that function in human cells and contain a paused pol II in vivo.
P-TEFb and Super Elongation Complex Stimulate Pause Release in the CFS
P-TEFb activity was originally described by Price and colleagues as necessary for pol II elongation in a DRB-sensitivity assay 27 . The targets of P-TEFb were identified by Handa and colleagues, also using a functional biochemical approach to purify DSIF and NELF 28, 29 . This line of investigation showed that DSIF and NELF were necessary for pol II pausing and P-TEFb activity released the paused polymerase into productive elongation. These three factors form the basis for our current understanding of pol II pausing. Figure 1 shows that elongation in the CFS is sensitive to flavopiridol, a known inhibitor of the CDK9 activity. In order to assay P-TEFb directly, the endogenous activity must be removed. This is easily done by conjugating biotinylated-CMV promoter template to magnetic beads. Using this assay system, one can isolate various steps in the transcription processes wash off soluble factors, and then add back the activity in question to assess its function 14, 30, 31 . As indicated in Figure 3A , a 30" pulse was used to label RNA and transcription was stopped with EDTA. The beads were separated from the nuclear extract using a magnet, washed several times in a buffer containing 60 mM KCl, and then resuspended in transcription buffer 31 . As shown in lane 1, Figure   3C , there is no full-length product synthesized after the addition of NTPs for the chase step. The addition of a concentrated 0.3M KCl fraction eluted from a P11 column 28 stimulated the production of full-length RNA (lane 2, Fig. 3C ). However, the addition of recombinant P-TEFb, purified from Sf9 cells (Fig. 3B ) further stimulated elongation (lane 2, Fig. 3C ), showing that the paused polymerases isolated on the immobilized templates are active and capable of being released into productive elongation.
The Super Elongation Complex (SEC) was identified by Shilatifard and colleagues and physically connects the ELL elongation factor to the P-TEFb kinase 32, 33 . Both can stimulate elongation in vitro by themselves and the SEC can stimulate elongation as a complex 34 . The question remains however, whether the SEC can stimulate pause release. Flag-tagged SEC 33 (F-SEC) was purified from 293 cells and western blot analysis showed that it contained several SEC subunits (E1-E3, Figure 3D ). The F-SEC also could phosphorylate rGST-CTD, as did rP-TEFb, as expected ( Figure 3E ) 33, 34 . Next, F-SEC was assayed using immobilized templates (Fig. 3F ).
Titration of F-SEC relative to the elution buffer (containing FLAG peptide) showed stimulation of isolated elongation complexes into intermediate and full-length RNA products (compare lanes 2-5 with 6-9, Fig. 3G ). Thus, these stably isolated, engaged, paused polymerases can enter productive elongation with either P-TEFb or SEC.
The O-GlcNAc Transferase is Necessary for RNA Polymerase II Pausing
O-GlcNAcylation is an important but underappreciated post-translational modification in higher eukaryotes. The modification is found on serine and threonine resides often in a mutually exclusive relationship with phosphorylation. This is problematic, as many serine to alanine substitutions were used to argue that phosphorylation was important in the protein in question. In contrast to the serine/threonine kinases and phosphatases, there is only one transferase, the OGlcNAc transferase (OGT) and one removal enzyme, O-GlcNAc aminidase (OGA) 35 . Previously it was shown that OGT is required for PIC formation 15, 16 and that OGA is required for proper elongation in the CFS 14 . The OGA elongation defect directly implicates an OGT catalytic requirement, which must occur prior to elongation, since OGA activity requires an OGlcNAcylated substrate.
To establish this requirement for O-GlcNAcylation, the substrate of OGT, UDP-GlcNAc, Figure 4D ), including the pausing factors DSIF and NELF 36, 37 .
Previously, addition of the OGT inhibitor ST045849 38 during PIC formation showed a transcription defect by primer extension assay 16 . Examination of the PIC composition suggested that ST045849 (hereafter referred to as STO4) blocked PIC formation as indicated by the absence of pol II 15 . However, one caveat of the primer extension assay used previously is that it does not allow one to observe the complete process of elongation. Therefore, the more informative pulse- More recently, the Walker lab has developed several additional OGT inhibitors 39 . Titration of these inhibitors post-PIC formation showed an increase in full-length RNA relative to the untreated and DMSO-treated nuclear extract with both OSMI-2a and OSMI-4a (compare lanes 1 and 2 to lanes 3 and 4, Fig. 5C ). Further refinement of the ST04 titration showed the same effects: a significant increase in the full-length RNA product and the apparent escape of the paused pol II population, especially the population just above +20 (lanes 5-7, Figure 5C ). As the ST04 concentration increased, a second effect appeared closer to the full-length RNA at 548 nt (as seen in lane 4, Fig. 5A and lanes 3 and 6, Fig. 5B ), suggesting a second OGT requirement for elongation into a full-length RNA at 548nt. These experiments, using four different OGT inhibitors, show that OGT activity is necessary to establish a paused pol II, and in the absence of OGT, the pol II does not pause, but immediately moves into an elongation phase.
If OGT is required for pausing, then the addition of rOGT and UDP-GlcNAc should reverse the effects of ST04. This experiment is readily done with immobilized templates. PICs were formed for 30', then, where indicated, ST04 was added for 10'. Transcription was initiated with a 30" pulse followed by inhibition with 20 mM EDTA. The beads were then isolated using a magnet, washed with transcription buffer to remove STO4, NTPs, and nuclear extract, and then resuspended in transcription buffer. To the indicated reactions rOGT or rOGT plus UDP-GlcNAc was added for 15', followed by a 5' chase with cold NTPs ( Figure 5D ). As expected, the untreated templates did not appreciably elongate after washing and the ST04 reaction showed much higher levels of RNAs longer than +75 (lanes 1 and 2, Fig. 5E ). The addition of rOGT has a slight effect on the levels of these RNAs (lane 3, Fig. 5E ) but the addition of both rOGT and its nucleotidesugar substrate UDP-GlcNAc dramatically suppressed the levels of RNAs longer than +75 (lane 4, Fig. 5E ), indicating that OGT catalytic activity reversed the inhibitory effect of ST04. This experiment shows that OGT catalytic activity is directly necessary for establishment of the paused pol II.
Discussion

Recapitulation of RNA pol II pausing
We present here evidence that a human cell-free system (CFS) recapitulates the expected behaviors of pol II pausing and elongation. It shows the expected sensitivity to CDK7 and CDK9
inhibitors which were previously established in vivo and in other CFSs. The CFS is also dependent on CDK12 and PARP catalytic activities, whose requirements had been established by in vivo experiments 10,23 , but which remained to be seen in a direct, biochemical transcription assay. These data also show that the effects of CDK12 and PARP observed in vivo are due to direct effects on pol II elongation and not indirect, genetic effects or system-wide effects due to drug inhibition and shRNA knockdown.
The CFS establishes a bona fide paused pol II, based on ten different criteria (Figures 1-3 ).
1) The CFS synthesizes a population of paused RNAs found between +20 and +75 downstream of the TSS. 2) These RNAs are stably engaged to the DNA template and remain associated with the pol II.
3) The +20/+75 RNA population does not chase into longer RNAs. 4) Sarkosyl treatment of this population on washed immobilized templates results in the release of the pol II and the synthesis of longer RNAs. 5) The treatment of the CFS with the CDK9 inhibitor flavopiridol inhibits elongation after +75 but does not perturb the +20/+75 RNA population. 6) The conclusions for flavopiridol also apply to the PARP-1 inhibitor PJ34. 7) In contrast, treatment with the CDK7 inhibitor, THZ1, eliminates the +20/+75 RNA population, as observed in other experiments 19, 20 . 8) Excess SPT5 results in the synthesis of RNAs longer than +75, as expected if titrating out associated pausing factors. 9) The +20/+75 RNA population is released upon treatment with either rP-TEFb or purified SEC. 10) Price and colleagues recently showed by PRO-seq analysis that in vivo the CMV IE promoter (and all other CMV promoters) are in fact paused 40 .
These data directly show that the CFS establishes an engaged, paused RNA pol II population between +20 and +75 and which will enter productive elongation under proper stimuli.
These data indicate that nucleosomes likely do not play a role in establishing or maintaining a paused pol II since there is no chromatin in our system. This is consistent with the CMV genome in vivo which displays pausing at all viral promoters but is not packaged into chromatin 40 . The positioning of a nucleosome downstream of the paused pol II never strongly supported that interpretation either 13 .
Additional elongation regulatory steps
In analyzing the elongation behaviors in the CFS, it became apparent that there is a second regulated elongation step further downstream of the paused pol II. The THZ1 and THZ531
inhibitors block elongation at approximately +400 ( Figure 1 ). The Sarkosyl-released RNAs do not extend to full-length nor do the GST-SPT5-released RNAs (Figure 2 ). ST04 also inhibits elongation past +400 ( Figure 5 ) suggesting not only that there is a regulatory point at +400 but that it is OGT-dependent. These data indicate that pause release is not necessarily equivalent to efficient elongation. Note that not all inhibitors behaved this way. PJ34 and flavopiridol completely block elongation without affecting the paused pol II population, while the THZ1, THZ531, and OGT inhibitors effect an apparently aberrant release but one that does not produce a full-length transcript. Such regulatory "checkpoints" have been noted previously using GROseq assays and CDK9 inhibitors 41 .
O-GlcNAc cycling is necessary for RNA pol II pausing and elongation
O-GlcNAc ChIP-seq peaks overlap paused pol II positions in human BJAB cells 14 .
Additionally, mass spectroscopy data indicated that both DSIF and NELF pausing factors are OGlcNAcylated 36 , as is pol II 16, 42 , and these might account for those observed ChIP-seq peaks.
Previous experiments showed that inhibition of OGA in the CFS blocked elongation 14 , as effectively as the CDK9 and PARP-1 inhibitors in this study. Those experiments indicated that OGA catalytic activity was required for elongation and secondly, that OGT must have acted prior to that point in order to create a substrate for the OGA.
The experiments herein confirmed this hypothesis and showed that OGT inhibition allowed pol II to bypass a pausing step and proceed into elongation ( Figure 5 ). The rescue of the OGT inhibition showed that this was a direct consequence of OGT catalytic activity and is supported by the titration of UDP-GlcNAc into the CFS, which blocked synthesis of a full-length RNA product We suggest here that one function of the CDK7, CDK12/13, and/or OGT catalytic activities is to create these irreversible kinetic proofreading steps. The reason that these evolutionarily more distant organisms do not have pausing is that their genomes are small enough that the ratio of specific to nonspecific transcription is such that the nonspecific events are relatively negligible.
These catalytic activities all utilize high energy donor compounds from various metabolic pathways. The OGT substrate UDP-GlcNAc is made from fructose-6-phosphate that originates from an early step in glycolysis. The PARP substrate NAD+ is derived from tryptophan and may also reflect the state of the Krebs cycle. Finally, ATP is of course the output from oxidative phosphorylation. Thus, if these enzymes are responsive to the metabolic flux of their substrates, then the preinitiation complex/paused pol II/pol II release at the 5' proximal end of genes may then be a sensor of the nutrient/metabolic state of the cell, modulating transcriptional output in response to changing metabolic flux.
The cell-free transcription system
The lack of a human nuclear extract system that recapitulates pausing has hindered understanding of the regulation of the paused pol II. Pol II pausing is of paramount importance, as most genes now are known to be regulated at that stage and not at the earlier PIC formation/initiation stage. The cell-free system described here will allow one to further explore the depths of pol II pausing, the factors involved in this step, and how pausing and pause release might be regulated. Such a system also allows one to directly probe these events, in contrast to the indirect genetic experiments to which one must resort for in vivo studies. Through the combination of the bottom-up functional biochemistry and in vivo genetic approaches, one should be able to further understand RNA pol II pausing and its regulation. 
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